The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario for ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...

A new drug could change everything for children like seven-year-old daughter, Liliana, who has Prader-Willi syndrome, a rare ...

Over the last 7 days, the United States market has dropped 3.4%, yet it remains up by 6.1% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context, ...